Jiangsu Hengrui Pharmaceuticals (600276.SH): Sodium citrate blood filtration replacement solution approved for market launch.
Hengrui Pharmaceutical (600276.SH) announced that its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. has recently received a national ...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Fujian Shengdi Pharmaceuticals Co., Ltd., has received notification from the National Medical Products Administration (NMPA) approving the listing of sodium citrate blood filtration replacement solution.
Approved indications: This product can be used as a replacement solution for continuous renal replacement therapy (CRRT) using local citrate anticoagulation. Citrate is particularly suitable for cases where systemic anticoagulation with heparin is contraindicated, such as in patients at increased risk of bleeding. If equipment matching the weight of pediatric patients can be used, this product is suitable for children of all ages.
Related Articles
Skyworth Digital (000810.SZ) Several directors and senior executives plan to collectively reduce their holdings by no more than 9.96 million shares.
DTXS SILK ROAD (00620) appoints Cai Hongtu as an independent non-executive director.
US Stock Market Move | After a sharp drop, Tesla, Inc. (TSLA.US) rebounded over 4%. Trump stated "not particularly interested" in talking to Musk.
Skyworth Digital (000810.SZ) Several directors and senior executives plan to collectively reduce their holdings by no more than 9.96 million shares.
DTXS SILK ROAD (00620) appoints Cai Hongtu as an independent non-executive director.
US Stock Market Move | After a sharp drop, Tesla, Inc. (TSLA.US) rebounded over 4%. Trump stated "not particularly interested" in talking to Musk.
